Novel TGF-β inhibitors ready for prime time in onco-immunology
Explore this paper's citation graph
Summary
From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that the TGF-β inhibitors have moved from promising to effective drug nominees.
- Type
- article
- Published
- 2016-12-07
- Cited by
- 167
- References
- 12
- OpenAlex
- https://openalex.org/W28197376
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10301488
Keywords
Physics, Meson, Lepton, Particle physics, RADIUS
References
- Targeting the TGFβ pathway for cancer therapy.
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
- Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
- TGFβ signalling in context
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- A phase 2 study of a novel transforming growth factor-beta (TGF-beta1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).
- Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
- OT-101: An anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies.
- A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).
- A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).
Cited by
- TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects
- TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity.
- Molecular Events in the Natural History of Pancreatic Cancer.
- Overcoming immunosuppression in bone metastases.
- New insights into the role of EMT in tumor immune escape
- Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis
- Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
- Trial Watch: Adoptively transferred cells for anticancer immunotherapy
- A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Periplaques of Spinal Cords from Progressive Multiple Sclerosis Patients
- Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
- Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring.
- A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Spinal Cord Periplaques from Progressive Multiple Sclerosis Patients
- CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
- Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines
- Understanding fibrosis in eosinophilic esophagitis: Are we there yet?
- Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation.
- Periostin, a signal transduction intermediate in TGF-β-induced EMT in U-87MG human glioblastoma cells, and its inhibition by anthocyanidins
- Transforming growth factor‐&bgr;1 impairs lymph node homing of dendritic cells by downregulating C‐type lectin receptor‐2 expression
- Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner
- Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma
Related papers
- Soft-momentum quark-model predictions for the pseudoscalar-meson decays into lepton pairs
- Leptonic decays of mesons in the quark bag model
- T-odd asymmetry in the decays of heavy particles
- Chiral description of radiative decays of charged kaons
- Form factors in radiative decays of pseudoscalar and vector mesons
- Measurement of the pion form factor in the reaction e/sup +/e/sup -/. --> pi. /sup +/. pi. /sup -/ in the energy range 0. 40--0. 46 GeV
- THE BRANCHING RATIO OF THE DECAY OF THE K + -MESON
- Study of the reaction. pi. /sup -/p. --> pi. /sup 0/. pi. /sup 0/n at 25 GeV/c